Tackling EBV-Associated Lymphoma: Early Research Finds Overall Survival Benefit After Donor Transplants

Share this content:
Infection with the EBV virus has been linked to several cancers, including nasopharyngeal cancers, Hodgkin lymphoma, and diffuse large B-cell lymphoma.
Infection with the EBV virus has been linked to several cancers, including nasopharyngeal cancers, Hodgkin lymphoma, and diffuse large B-cell lymphoma.

Donor-derived T cells that target proteins of the Epstein-Barr virus (EBV) in relapsed or refractory lymphoma can improve overall survival in the adjuvant setting, according to research from a small study that was recently published in Blood.1

The experimental T cells were infused into 26 patients, who received an allogeneic bone marrow transplant for EBV-associated lymphomas. Seven patients had active disease at the time of infusion, while 19 received the T cells after transplant as adjuvant therapy for high-risk disease.

“These patients were the sickest of the sick,” having exhausted other treatment options, said Catherine M. Bollard, MD, the principal investigator, who began the phase 1 clinical trial at Baylor College of Medicine in Houston, Texas, before opening a tandem trial at Children's National in Washington, District of Columbia.

Those who had the best outcome after T-cell therapy had B-cell diseases, a finding investigators attributed, in part, to B cells' antigen-presenting role in the body, Dr Bollard said.Two-year overall survival reached 80%, which is 12% higher than the patient group as a whole.

Infection with the EBV virus has been linked to a number of cancers, including over 90% of nasopharyngeal cancers, up to 40% of Hodgkin lymphoma, and 20% of diffuse large B-cell lymphoma, among others.2

Researchers have identified at least 9 EBV proteins, along with different phases of protein expression during the virus' latent or dormant period. Type III latency, in which tumors express all 9 membrane proteins, are considered the most immunogenic and the most amenable to EBV-directed T-cell therapies, Dr Bollard said. Although the type II latency tumors treated in the current study were less immunogenic, targeting them prevented relapse in high-risk patients (after transplant) without significant toxicity.

In the study, patients with active disease at the time of T-cell infusion fared poorly compared with patients receiving adjuvant therapy, explained Dr Bollard. But, these patients still did slightly better than expected, given a less than 20% chance for a good outcome if relapse occurs following transplant.

In general, patients with T-cell-mediated lymphoma also did better than expected. Two-year overall survival in this group reached 60%, compared with previously published 2-year posttransplant survival rates of approximately 30%.

How soon EBV-specific T-cell therapies might be licensed is uncertain and is awaiting further study. 

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs